GCC tafamidis pricing is transitioning: private-import pricing near SAR 820,000-850,000/year describes the pre-registration state, and post-registration MOH tender pricing near SAR 70,000-90,000 describes what follows.
Tafamidis (Vyndaqel) access in the GCC spans two distinct pricing regimes, and reconciling them requires tracking registration status rather than treating either figure as the single true price. Before SFDA registration is complete, patients access tafamidis through private import or VHI special-import arrangements at a WAC-equivalent near SAR 820,000-850,000 a year, materially above NPHC and typical GCC patient willingness to pay. Once SFDA registration and the MOH tender process complete, the same drug prices at SAR 70,000-90,000 a year, a discount of roughly 90 percent, achieved through GCC reference pricing against Portugal and Greece plus direct MOH negotiation. UAE tender pricing follows a similar pattern at AED 55,000-75,000 a year. Unlike PNH or SMA, NPHC has not established a formal ATTR-CM coverage programme, so access proceeds case-by-case through cardiologist prescription plus MOH or hospital pharmacy committee approval, with an estimated approval rate of 50 to 60 percent of submitted cases.
A pricing model built on either state alone will mislead a new entrant. Modelling only the private-import price overstates what the market will bear once registration completes; modelling only the tender price assumes an infrastructure that, for a given country or drug, may not yet exist. Our price ladder tracks both states explicitly and treats the transition itself, not a single point estimate, as the modelling unit. Because GCC registration status changes faster than published sources are updated, this model flags GCC registration status as a live variable that should be reconfirmed against current SFDA and NPHC records before use in a specific pricing decision.
GCC ATTR pricing — two price regimes on either side of SFDA registration
| Registration State | Tafamidis Pricing | Mechanism | Applies To |
|---|---|---|---|
| Pre-registration (private import) | ~SAR 820,000-850,000/yr WAC-equivalent | VHI special-import, case-by-case approval | Markets or periods before SFDA registration completes |
| Post-registration (SFDA + MOH tender) | ~SAR 70,000-90,000/yr (~90% discount) | SFDA registration plus MOH tender negotiation against EU reference prices | Markets or periods after registration and tender pricing are set |
| UAE tender (comparator) | AED 55,000-75,000/yr | Dubai/Abu Dhabi MOH tender negotiation | Cross-check for KSA tender pricing |
Sources: Saudi MOH drug procurement data 2023; UAE DHA drug pricing database 2023; Pfizer GCC pricing disclosures; SFDA drug registration guidelines 2023.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The registration-status transition explained
- pre- versus post-registration price ladder
- guidance on which figure applies to a given country and timeframe
Delivers
- NPHC programme-scope gap versus PNH/SMA precedent
- MOH/hospital pharmacy committee approval mechanics
- the 50-60% approval-rate implication for volume forecasting
Delivers
- The Portugal/Greece reference-pricing mechanism
- KSA versus UAE (AED 55,000-75,000/year) tender comparison
- the negotiation depth a new entrant should expect
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why registration status, not negotiation skill, determines which of two GCC price points applies
- Pressure-tested against the pre- and post-registration tafamidis precedent before the rest of the model is built out
- How the SAR 820,000-850,000 pre-registration price compares with the SAR 70,000-90,000 post-registration tender price
- Where a new entrant's own registration timeline places it on that ladder
- Why ATTR-CM has no formal NPHC programme, unlike PNH or SMA
- The 50-60% approval-rate implication for launch volume forecasting
- AED 55,000-75,000/year UAE tender pricing as the cross-market comparator
- What the analogue supports for a defensible KSA and UAE launch price
- How pricing is set absent a published GCC QALY or ICER-style threshold
- Where evidence strength could support pricing above the tender floor
- The reference-price, negotiation-discount, and tender components decomposed line by line
- The ~90% discount depth already observed once registration completes
- Sequencing recommendation tied to each country's registration timeline
- Conservative, base, and aggressive revenue scenarios for pre- and post-registration states
- Confirm current SFDA/NPHC registration status before the launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources, SFDA registration data, MOH tender documentation, and NPHC programme records, not secondary summaries. Findings are independently verified before inclusion.
GCC ATTR pricing sources: Saudi MOH drug procurement data 2023, UAE DHA drug pricing database 2023, Pfizer GCC pricing disclosures, and SFDA drug registration guidelines 2023. Because GCC registration status for tafamidis has been reported differently across source periods, this model treats registration status as a transitioning variable rather than a fixed fact, and flags it for reconfirmation against current SFDA and NPHC records before use in a specific pricing decision.
- Pre-registration private-import pricing verified against Pfizer GCC pricing disclosures and case-by-case VHI import records
- Post-registration MOH tender pricing verified against Saudi MOH drug procurement data 2023
- UAE comparator tender pricing verified against the UAE DHA drug pricing database 2023
- GCC registration-status transition flagged for reconfirmation against current SFDA and NPHC records before use in a live pricing decision
Frequently asked questions
Commission this model
AXLRx delivers ATTR pricing strategy models built for market access and pricing teams navigating the GCC's pre- and post-registration price transition. Custom model in 72 hours.
Specify your target GCC country, current registration status, and comparator scope.
AXLRx analyst reconfirms live SFDA/NPHC registration status and pricing assumptions before building.
Research-verified pricing model in 72 hours with optional analyst readout.